These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 34732320)

  • 1. N-alpha-acetylation of Huntingtin protein increases its propensity to aggregate.
    Gottlieb L; Guo L; Shorter J; Marmorstein R
    J Biol Chem; 2021 Dec; 297(6):101363. PubMed ID: 34732320
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The chaperone-like protein HYPK acts together with NatA in cotranslational N-terminal acetylation and prevention of Huntingtin aggregation.
    Arnesen T; Starheim KK; Van Damme P; Evjenth R; Dinh H; Betts MJ; Ryningen A; Vandekerckhove J; Gevaert K; Anderson D
    Mol Cell Biol; 2010 Apr; 30(8):1898-909. PubMed ID: 20154145
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acetylation within the First 17 Residues of Huntingtin Exon 1 Alters Aggregation and Lipid Binding.
    Chaibva M; Jawahery S; Pilkington AW; Arndt JR; Sarver O; Valentine S; Matysiak S; Legleiter J
    Biophys J; 2016 Jul; 111(2):349-362. PubMed ID: 27463137
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aggregation landscapes of Huntingtin exon 1 protein fragments and the critical repeat length for the onset of Huntington's disease.
    Chen M; Wolynes PG
    Proc Natl Acad Sci U S A; 2017 Apr; 114(17):4406-4411. PubMed ID: 28400517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The dynamics of early-state transcriptional changes and aggregate formation in a Huntington's disease cell model.
    van Hagen M; Piebes DGE; de Leeuw WC; Vuist IM; van Roon-Mom WMC; Moerland PD; Verschure PJ
    BMC Genomics; 2017 May; 18(1):373. PubMed ID: 28499347
    [TBL] [Abstract][Full Text] [Related]  

  • 6. N-terminal Huntingtin (Htt) phosphorylation is a molecular switch regulating Htt aggregation, helical conformation, internalization, and nuclear targeting.
    DeGuire SM; Ruggeri FS; Fares MB; Chiki A; Cendrowska U; Dietler G; Lashuel HA
    J Biol Chem; 2018 Nov; 293(48):18540-18558. PubMed ID: 30185623
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A New Chemoenzymatic Semisynthetic Approach Provides Insight into the Role of Phosphorylation beyond Exon1 of Huntingtin and Reveals N-Terminal Fragment Length-Dependent Distinct Mechanisms of Aggregation.
    Kolla R; Gopinath P; Ricci J; Reif A; Rostami I; Lashuel HA
    J Am Chem Soc; 2021 Jul; 143(26):9798-9812. PubMed ID: 34161085
    [TBL] [Abstract][Full Text] [Related]  

  • 8. N-terminal mutant huntingtin deposition correlates with CAG repeat length and symptom onset, but not neuronal loss in Huntington's disease.
    Layburn FE; Tan AYS; Mehrabi NF; Curtis MA; Tippett LJ; Turner CP; Riguet N; Aeschbach L; Lashuel HA; Dragunow M; Faull RLM; Singh-Bains MK
    Neurobiol Dis; 2022 Nov; 174():105884. PubMed ID: 36220612
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HSP90 recognizes the N-terminus of huntingtin involved in regulation of huntingtin aggregation by USP19.
    He WT; Xue W; Gao YG; Hong JY; Yue HW; Jiang LL; Hu HY
    Sci Rep; 2017 Nov; 7(1):14797. PubMed ID: 29093475
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phosphorylation of threonine 3: implications for Huntingtin aggregation and neurotoxicity.
    Aiken CT; Steffan JS; Guerrero CM; Khashwji H; Lukacsovich T; Simmons D; Purcell JM; Menhaji K; Zhu YZ; Green K; Laferla F; Huang L; Thompson LM; Marsh JL
    J Biol Chem; 2009 Oct; 284(43):29427-36. PubMed ID: 19710014
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mass spectrometric identification of novel lysine acetylation sites in huntingtin.
    Cong X; Held JM; DeGiacomo F; Bonner A; Chen JM; Schilling B; Czerwieniec GA; Gibson BW; Ellerby LM
    Mol Cell Proteomics; 2011 Oct; 10(10):M111.009829. PubMed ID: 21685499
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TBK1 phosphorylates mutant Huntingtin and suppresses its aggregation and toxicity in Huntington's disease models.
    Hegde RN; Chiki A; Petricca L; Martufi P; Arbez N; Mouchiroud L; Auwerx J; Landles C; Bates GP; Singh-Bains MK; Dragunow M; Curtis MA; Faull RL; Ross CA; Caricasole A; Lashuel HA
    EMBO J; 2020 Sep; 39(17):e104671. PubMed ID: 32757223
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The emerging role of the first 17 amino acids of huntingtin in Huntington's disease.
    Arndt JR; Chaibva M; Legleiter J
    Biomol Concepts; 2015 Mar; 6(1):33-46. PubMed ID: 25741791
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A human huntingtin SNP alters post-translational modification and pathogenic proteolysis of the protein causing Huntington disease.
    Martin DDO; Kay C; Collins JA; Nguyen YT; Slama RA; Hayden MR
    Sci Rep; 2018 May; 8(1):8096. PubMed ID: 29802276
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interaction of huntingtin with PRMTs and its subsequent arginine methylation affects HTT solubility, phase transition behavior and neuronal toxicity.
    Ratovitski T; Jiang M; O'Meally RN; Rauniyar P; Chighladze E; Faragó A; Kamath SV; Jin J; Shevelkin AV; Cole RN; Ross CA
    Hum Mol Genet; 2022 May; 31(10):1651-1672. PubMed ID: 34888656
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Huntingtin protein: A new option for fixing the Huntington's disease countdown clock.
    Caterino M; Squillaro T; Montesarchio D; Giordano A; Giancola C; Melone MAB
    Neuropharmacology; 2018 Jun; 135():126-138. PubMed ID: 29526547
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Post-translational modifications clustering within proteolytic domains decrease mutant huntingtin toxicity.
    Arbez N; Ratovitski T; Roby E; Chighladze E; Stewart JC; Ren M; Wang X; Lavery DJ; Ross CA
    J Biol Chem; 2017 Nov; 292(47):19238-19249. PubMed ID: 28972180
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative study of naturally occurring huntingtin fragments in Drosophila points to exon 1 as the most pathogenic species in Huntington's disease.
    Barbaro BA; Lukacsovich T; Agrawal N; Burke J; Bornemann DJ; Purcell JM; Worthge SA; Caricasole A; Weiss A; Song W; Morozova OA; Colby DW; Marsh JL
    Hum Mol Genet; 2015 Feb; 24(4):913-25. PubMed ID: 25305076
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological characterization of mutant huntingtin aggregate-directed PET imaging tracer candidates.
    Herrmann F; Hessmann M; Schaertl S; Berg-Rosseburg K; Brown CJ; Bursow G; Chiki A; Ebneth A; Gehrmann M; Hoeschen N; Hotze M; Jahn S; Johnson PD; Khetarpal V; Kiselyov A; Kottig K; Ladewig S; Lashuel H; Letschert S; Mills MR; Petersen K; Prime ME; Scheich C; Schmiedel G; Wityak J; Liu L; Dominguez C; Muñoz-Sanjuán I; Bard JA
    Sci Rep; 2021 Sep; 11(1):17977. PubMed ID: 34504195
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design and characterization of mutant and wildtype huntingtin proteins produced from a toolkit of scalable eukaryotic expression systems.
    Harding RJ; Loppnau P; Ackloo S; Lemak A; Hutchinson A; Hunt B; Holehouse AS; Ho JC; Fan L; Toledo-Sherman L; Seitova A; Arrowsmith CH
    J Biol Chem; 2019 Apr; 294(17):6986-7001. PubMed ID: 30842263
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.